Xencor (NASDAQ:XNCR) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.

Other equities analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. ValuEngine raised shares of Xencor from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Cantor Fitzgerald began coverage on shares of Xencor in a research note on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price on the stock. Finally, Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the stock a “buy” rating in a research note on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.80.

Shares of Xencor (XNCR) traded up $0.01 during mid-day trading on Thursday, reaching $22.26. 144,848 shares of the company’s stock were exchanged, compared to its average volume of 215,764. Xencor has a one year low of $18.55 and a one year high of $28.64.

In related news, major shareholder John S. Stafford III purchased 24,653 shares of Xencor stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of $20.01 per share, with a total value of $493,306.53. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder John S. Stafford III purchased 50,000 shares of Xencor stock in a transaction dated Thursday, November 2nd. The stock was bought at an average cost of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. Insiders have acquired 263,105 shares of company stock worth $5,206,858 over the last ninety days. 4.03% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can raised its stake in shares of Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the period. SG Americas Securities LLC raised its stake in shares of Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of Xencor in the 3rd quarter valued at approximately $201,000. Legal & General Group Plc raised its stake in shares of Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in shares of Xencor in the 2nd quarter valued at approximately $224,000. 77.62% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/xencor-xncr-lifted-to-sell-at-bidaskclub.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.